Trials / Recruiting
RecruitingNCT04914026
MicroRNA as Markers in Testicular Cancer
MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 350 (estimated)
- Sponsor
- Haukeland University Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is establish the performance of miR371 in management of testicular cancer
Detailed description
The main objective of the study is to asses the sensitivity and specificity of microRNA-371a-5p (miR371) in detection of viable testicular germ tumour cells. To assess the utility of miR371 at orchiectomy, during treatment and surveillance and in early detection of recurrence.
Conditions
- Testicular Germ Cell Cancer
- Seminoma
- Non-Seminoma Testicular Cancer
- Stage I Testicular Cancer
- Stage II Testicular Cancer
- Stage III Testicular Cancer
- Stage IV Testicular Cancer
- Relapse Testicular Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biomarker analysis | Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months |
Timeline
- Start date
- 2016-12-31
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2021-06-04
- Last updated
- 2022-08-08
Locations
6 sites across 2 countries: Norway, Sweden
Source: ClinicalTrials.gov record NCT04914026. Inclusion in this directory is not an endorsement.